J. M. Sloan, MD

Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Factotum hematologist at Boston Medical Center
Associate Professor at Chobanian and Avedisian School of Medicine.
Program director for the hematology/oncology fellowship at Boston University.
I see patients with a variety of benign and malignant blood disorders.
I have particular research interests in AL Amyloidosis, HTLV-1 associated leukemia/lymphoma (ATLL)

Publications

  • Published 12/12/2025

    Ferri GM, Martinez CB, Acevedo J, Bhatt S, Verma KP, Lee J, Abdallah M, Szalat RE, Sloan JM. Exploring the effect of Duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors. Breast Cancer Res Treat. 2025 Dec 12; 215(1):36. PMID: 41385110.

    Read at: PubMed

  • Published 9/22/2025

    Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R. Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis-Related Acquired Factor X Deficiency. Am J Hematol. 2025 Dec; 100(12):2416-2420. PMID: 40981270.

    Read at: PubMed

  • Published 9/16/2025

    Parekh A, Lerner A, Thomasson RR, Sloan JM. Incidence of Typical Neutrophil Count With Fy(a-b-) Status Among Hematology Referrals for Neutropenia at an Urban Safety-Net Hospital. Adv Hematol. 2025; 2025:2488148. PMID: 40994727.

    Read at: PubMed

  • Published 9/2/2025

    Avila Rodriguez AM, Hu X, Varga C, Comenzo R, Sarosiek S, Sloan JM, Sanchorawala V, Doros G, Quillen K. Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as outpatient versus inpatient. Br J Haematol. 2025 Oct; 207(4):1679-1683. PMID: 40898649.

    Read at: PubMed

  • Published 6/3/2025

    Dittus C, Weinstock MJ, Barnes J, Sandoval-Sus J, Grover NS, Beaven A, Hoye K, Shelton A, Tan X, Srinivasan MD, El-Jawahri A, Sarosiek S, Sloan JM. Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma. Br J Haematol. 2025 Jun 03. PMID: 40459047.

    Read at: PubMed

Other Positions

  • Member, BU-BMC Cancer Center
    Boston University
  • Member, Amyloidosis Center
    Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research
    Boston University

Education

  • Yale University School of Medicine, MD
  • Haverford College, BS